Other FDA Approved

Gallium Ga-68 Dotatoc

A positron-emitting somatostatin analog in which the octapeptide DOTA-Tyr3-octreotide (edotreotide) carries gallium-68 to somatostatin receptor-positive cells, FDA approved since 2019 under an academic application from the University of Iowa as a PET agent for localizing neuroendocrine tumors.

RadiopharmaceuticalSomatostatin AnalogNeuroendocrinePET ImagingFDA Approved

Also referenced as: Gallium Ga 68 edotreotide, 68Ga-DOTATOC, Ga-68 DOTATOC, 68Ga-DOTA-TOC, 68Ga-edotreotide, SomaKit TOC, LNTH-2501

Also appears in: Hormone

Public product evidence No certificate records are bound to a tracked Gallium Ga-68 Dotatoc product page A record counts here only when a vendor publishes a certificate against one of its own tracked Gallium Ga-68 Dotatoc product pages. Other certificates naming this compound may still exist — search the wider certificate database.
Status
FDA Approved

This compound maps to at least one regulated medical product or label context in the United States.

Research area
Other research areas

Primary research area: Other. Also surfaces under Hormone for browsing and discovery.

Body systems
Gut · Hormones

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases
7

Gallium Ga 68 edotreotide, 68Ga-DOTATOC, Ga-68 DOTATOC, 68Ga-DOTA-TOC, 68Ga-edotreotide, SomaKit TOC, LNTH-2501

Signal depth
Medium

FDA label signal · 154 trials · 294 PubMed results

Established

Gallium Ga-68 Dotatoc is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.

Gallium Ga-68 Dotatoc has 8 name-matched clinical trials (highest phase: Phase 3) and 294 PubMed-indexed publications and holds an FDA drug label. Human trials are registered but none have posted results yet.

Human data
Approved drug
Trial quality
Randomized
Outcomes
Surrogate / early
Replication
Meta-analysis
Literature
High-impact

Re-checked nightly against the registries — tracked since 2026-11-17. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-18 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →


What is Gallium Ga-68 Dotatoc?

Gallium Ga-68 dotatoc is a radiolabeled somatostatin analog: the cyclic octapeptide Tyr3-octreotide, in which the phenylalanine at position 3 of octreotide is replaced by tyrosine, linked through the chelator DOTA to the positron emitter gallium-68. The US label gives the sequence D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr with one disulfide bond and a molecular weight of 1,489.65 g/mol for the gallium complex. The peptide keeps the C-terminal threoninol of octreotide, the single residue separating it from gallium Ga-68 dotatate, whose octreotate vector ends in threonine. The unlabeled DOTA-peptide conjugate carries the international nonproprietary name edotreotide, and since a July 2023 labeling supplement the US established name has been gallium Ga 68 edotreotide. The same edotreotide peptide is the vector of the investigational therapeutic lutetium-177 edotreotide, just as dotatate is shared with lutetium Lu-177 dotatate.

Its regulatory history is unusual. 68Ga-DOTATOC was first reported clinically in 2001 and was used in European academic centers for nearly two decades without a commercial sponsor; the first US approval, on August 21, 2019, went to an academic applicant, the University of Iowa Health Care PET Imaging Center, which filed NDA 210828 and makes the injection in its own facility. In the European Union it is marketed as the cold kit SomaKit TOC, authorized December 8, 2016. It is a diagnostic, not a treatment, exists as a finished drug for only a few hours after labeling, and has no presence in the research-peptide market.

How it works

  • Receptor binding. Well-differentiated neuroendocrine tumors (NETs) overexpress somatostatin receptors, especially subtype 2 (SSTR2). In receptor-transfected cell lines, Ga-DOTA-Tyr3-octreotide bound SSTR2 with an IC50 of 2.5 nM, while Ga-DOTA-Tyr3-octreotate bound about ten times more tightly (IC50 0.2 nM) (Reubi et al., European Journal of Nuclear Medicine, 2000, 27(3):273-282). The US label gives a Ki of 2.5 ± 0.5 nM for SSTR2 and states that image intensity reflects receptor density, so NETs without the receptor are not visualized.
  • Positron emission and clearance. Gallium-68 decays with a 68-minute half-life to stable zinc-68, emitting a positron in about 89% of decays; annihilation yields the paired 511 keV photons a PET scanner detects. In the first clinical study, arterial activity cleared bi-exponentially with half-lives of 2.0 and 48 minutes, no radioactive metabolites appeared in serum within 4 hours, tumor uptake peaked about 70 minutes after injection and kidney uptake averaged less than half of spleen uptake (Hofmann et al., European Journal of Nuclear Medicine, 2001, 28(12):1751-1757). Elimination is exclusively urinary.
  • Affinity does not translate into lesion count. In a within-patient comparison of 40 patients, 68Ga-DOTATOC detected 262 lesions versus 254 for 68Ga-DOTATATE (p < 0.05), with a higher mean SUVmax (20.4 versus 16.0; p < 0.01) and no difference in renal uptake, leading the authors to conclude that the roughly tenfold in vitro affinity gap is not clinically relevant (Poeppel et al., Journal of Nuclear Medicine, 2011, 52(12):1864-1870).
  • Receptor competition and physiologic uptake. Unlabeled somatostatin analogs such as octreotide and lanreotide occupy the same receptors and can reduce tracer uptake. Normal pituitary, spleen, adrenals, kidneys, pancreas and liver take up the tracer, and in the Innsbruck series the single false-positive scan was caused by enhanced tracer accumulation in the pancreatic head (Gabriel et al., Journal of Nuclear Medicine, 2007, 48(4):508-518); the label adds the uncinate process of the pancreas, thyroid disease, subacute inflammation and other receptor-expressing tumors as sources of uptake that is not a NET.

Research status

The US application rested on two single-center Iowa studies plus a meta-analysis of two decades of European academic literature.

First-in-human (Hannover, 2001). In eight patients with histologically verified carcinoid tumors, 68Ga-DOTATOC PET identified 100% of 40 lesions predefined by CT or MRI, against 85% for 111In-octreotide planar and SPECT imaging, and found more than 30% additional lesions (Hofmann et al., European Journal of Nuclear Medicine, 2001, 28(12):1751-1757).

The Innsbruck prospective study. Gabriel et al. (Journal of Nuclear Medicine, 2007, 48(4):508-518) prospectively studied 84 patients with known or suspected NETs, reading PET, somatostatin receptor scintigraphy and CT independently against a reference of histology, imaging and follow-up. PET was true-positive in 69, true-negative in 12, false-positive in 1 and false-negative in 2, for a sensitivity of 97%, specificity of 92% and accuracy of 96%; scintigraphy was false-negative in 34 patients and CT in 26 (p < 0.001).

Meta-analyses. Yang et al. (Acta Radiologica, 2014, 55(4):389-398) pooled 10 studies and 416 patients and estimated per-patient sensitivity of 93% (95% CI 89% to 96%) and specificity of 85% (95% CI 74% to 93%) for 68Ga-DOTATOC, against 96% and 100% (95% CI 82% to 100%) for 68Ga-DOTATATE. The review written to support the US application, Graham et al. (Journal of Nuclear Medicine, 2017, 58(9):1452-1458), screened 468 papers from January 2001 through November 2015 and retained 17. Pooled sensitivity was 92% (12 papers) and specificity 82% (7 papers); the yield for locating an unknown primary in metastatic NET was 44%; management changed in 51% of patients; and in two direct comparisons with 111In-octreotide, per-lesion sensitivity was 100% for DOTATOC versus 78.2%. In patients with suggestive symptoms and biomarkers but negative conventional imaging the yield was only 13%, and no study reported an adverse event.

The Iowa program and the US label. Study A (NCT01619865), an investigator-sponsored phase 1/2 study at the University of Iowa, enrolled 223 participants from 2012 to 2017 to compare 68Ga-DOTATOC PET/CT with Octreoscan plus contrast-enhanced CT; Study B (NCT01869725) was a phase 2 comparator study of 68 participants completed in December 2018. In the label’s analysis, 282 patients received a single dose (age range 4 to 82), and two independent blinded readers scored each patient against a composite reference of histopathology, imaging within one year, chromogranin A and pancreastatin. Among 220 Study A patients, 177 were evaluable: positive agreement with the reference was 91% (95% CI 85% to 95%) for reader 1 and 90% (84% to 95%) for reader 2, with negative agreement of 89% (75% to 96%) and 86% (73% to 95%). Among 62 Study B patients, 59 were evaluable: positive agreement was 92% and 90% and negative agreement 75% for both readers. The pediatric indication rests on 14 children across the two studies, and safety was evaluated in 334 patients. From the same program, 68Ga-DOTATOC PET/CT located an unknown primary in 38% of 40 patients with metastatic NET, with 7% false-positive and 50% false-negative scans (Menda et al., Journal of Nuclear Medicine, 2017, 58(7):1054-1057), and prompted a major management change in 47% of 114 patients with SSTR2A-positive lung, pancreatic or small bowel NETs, with no drug-related grade 2 or 3 adverse events (Ghobrial et al., Pancreas, 2020, 49(8):1033-1036). Sunderland (Journal of Nuclear Medicine, 2020, 61(4):480-487) described the four-year academic NDA process.

Regulatory record. The FDA approved NDA 210828 on August 21, 2019 as a Type 1 new molecular entity under standard review with orphan designation. Supplement S-003, approved July 27, 2023, changed the established name to gallium Ga 68 edotreotide to match USAN and USP nomenclature. Drugs@FDA lists a second US product, an abbreviated new drug application (ANDA 218845) from an applicant recorded as Methodist, approved October 10, 2025. In the European Union, SomaKit TOC received orphan designation on March 19, 2015 and a Commission marketing authorization on December 8, 2016 for PET imaging of somatostatin receptor overexpression in adults with well-differentiated gastroenteropancreatic NETs; the authorization is held by Novartis Europharm. A third US route has not yet succeeded: Lantheus’s new drug application for LNTH-2501, a two-vial kit for on-site preparation of gallium Ga 68 edotreotide injection, drew a complete response letter that the company announced on June 26, 2026, citing unresolved third-party manufacturing facility conditions and no clinical deficiencies; no approval had been announced as of November 2026.

Current work. ClinicalTrials.gov lists 26 recruiting, not-yet-recruiting or active studies with DOTATOC or edotreotide as an intervention as of November 2026. Few test the diagnostic itself; most use 68Ga-DOTATOC for patient selection inside trials of radioligand therapy, including two ITM-sponsored phase 3 trials of lutetium-177 edotreotide (NCT03049189 and NCT04919226), or evaluate it outside the NET label, for example in metastatic breast cancer (NCT06611891). In 115 patients imaged with both methods, 68Ga-DOTATOC PET raised median Krenning scores from 2 to 3 over 111In-octreotide scintigraphy and increased radionuclide-therapy eligibility under NETTER-1 criteria from 59.1% to 81.7% (Fedrigo et al., Neuroendocrinology, 2026, 116(5):299-306).

Common dosage forms

  • Gallium Ga 68 Edotreotide Injection (University of Iowa Health Care PET Imaging Center). A ready-to-use solution in a 30 mL multiple-dose glass vial containing 18.5 to 148 MBq/mL (0.5 to 4 mCi/mL) at calibration, administered intravenously by nuclear medicine staff.
  • Gallium Ga 68 Edotreotide Injection (ANDA 218845). A generic solution of the same strength range approved in 2025.
  • SomaKit TOC (European Union). A cold kit for radiopharmaceutical preparation containing edotreotide, labeled with gallium-68 at the radiopharmacy.
  • LNTH-2501 (investigational). A two-vial kit for on-site preparation of gallium Ga 68 edotreotide injection, studied by Lantheus and not marketed.

Key considerations

  • Regulatory status. The FDA Approved status reflects the August 21, 2019 approval of Gallium Ga 68 Edotreotide Injection under NDA 210828, held by the University of Iowa Health Care PET Imaging Center, for PET localization of somatostatin receptor-positive neuroendocrine tumors in adult and pediatric patients. The application came from an academic center rather than a company, a generic (ANDA 218845) followed in October 2025, and the Lantheus kit remains unapproved after a June 2026 complete response letter.
  • A localization tool, not a diagnosis. Uptake reflects receptor density, so other receptor-expressing tumors, thyroid disease, subacute inflammation and the uncinate process of the pancreas can mimic a NET, and the label states that a negative scan in a patient without a history of NET does not rule out disease. The 13% yield in patients with suggestive symptoms and biomarkers but negative conventional imaging shows where the agent performs worst.
  • Evidence shape. The pivotal data are two single-center, open-label studies read against a composite reference rather than universal pathology, with negative agreement as low as 75% in Study B and a pediatric claim resting on 14 children. Pooled sensitivity is 92% to 93%, but specificity estimates range from 82% to 92% by review.
  • Safety signals. Adverse reactions in 334 patients were limited to nausea, pruritus and flushing at rates below 2%; the hypersensitivity warning, including angioedema and anaphylaxis-like features, is drawn from somatostatin receptor imaging agents as a class, and the agent adds to cumulative radiation exposure. Unlabeled somatostatin analogs can distort results through receptor competition.
  • Naming. Gallium Ga 68 edotreotide, gallium Ga 68 dotatoc, 68Ga-DOTATOC, 68Ga-DOTA-TOC, SomaKit TOC and LNTH-2501 all describe the same gallium-labeled DOTA-Tyr3-octreotide, whereas 68Ga-DOTATATE (NETSPOT) and copper Cu-64 dotatate (Detectnet) are different tracers sharing the target. Head-to-head data show comparable lesion detection, but results for one tracer are not validated for another.